GPC Biotech Merger With Agennix May Have A Billionaire’s Reasons For Success
This article was originally published in The Pink Sheet Daily
Key to the deal is investment by German billionaire Dietmar Hopps; GPC, troubled since satraplatin failed to meet trial endpoints, gains Agennix’s NCSLC candidate, talactoferrin.
You may also be interested in...
German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.
Latest action comes after the German drug maker announced a restructuring last year due to a Phase III setback with satraplatin.
Trials begin once the company completes a financing round, CEO Barsky tells "The Pink Sheet" DAILY.